Details of the Drug

General Information of Drug (ID: DM8V75C)

Drug Name

ABIRATERONE

Synonyms

Abiraterone (AR inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

L02BX03: ABIRATERONE

L02BX: Other hormone antagonists and related agents

L02B: HORMONE ANTAGONISTS AND RELATED AGENTS

L02: ENDOCRINE THERAPY

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

349.5

Logarithm of the Partition Coefficient (xlogp)

4.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 14 hours [2]
Metabolism: The drug is metabolized via the esterases []
Vd: The volume of distribution (Vd) of drug is 19,669 +/- 13,358 L []

Chemical Identifiers

Formula: C24H31NO
IUPAC Name: (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
Canonical SMILES: C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
InChI: InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
InChIKey: GZOSMCIZMLWJML-VJLLXTKPSA-N

Cross-matching ID

PubChem CID: 132971
ChEBI ID: CHEBI:68642
CAS Number: 154229-19-3
UNII: G819A456D0
DrugBank ID: DB05812
TTD ID: D02STN
ACDINA ID: D00004

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Steroid 17-alpha-monooxygenase (S17AH)	TTRA5BZ	CP17A_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Drug Response	[4]
Membrane cofactor protein (CD46)	OTQ8NWJD	MCP_HUMAN	Gene/Protein Processing	[5]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Gene/Protein Processing	[6]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Gene/Protein Processing	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

02 Neoplasm

Disease Class

ICD-11: 2C82 Prostate cancer

The Studied Tissue

Prostate

The Studied Disease

Prostate cancer [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Steroid 17-alpha-monooxygenase (S17AH)	DTT	CYP17A1	6.87E-01	0.07	0.21

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as ABIRATERONE

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Enzalutamide	DMGL19D	Major	Increased metabolism of ABIRATERONE caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[8]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of ABIRATERONE caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[9]
-----------

Coadministration of a Drug Treating the Disease Different from ABIRATERONE (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of ABIRATERONE and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[10]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Ivosidenib.	Acute myeloid leukaemia [2A60]	[11]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Midostaurin.	Acute myeloid leukaemia [2A60]	[12]
Arn-509	DMT81LZ	Major	Decreased metabolism of ABIRATERONE caused by Arn-509 mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[8]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Gilteritinib.	Acute myeloid leukaemia [2A60]	[12]
Oliceridine	DM6MDCF	Major	Decreased metabolism of ABIRATERONE caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[13]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Ivabradine.	Angina pectoris [BA40]	[12]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[14]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Levalbuterol.	Asthma [CA23]	[15]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of ABIRATERONE caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[8]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of ABIRATERONE caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[16]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of ABIRATERONE and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[17]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Eribulin.	Breast cancer [2C60-2C6Y]	[12]
Tucatinib	DMBESUA	Major	Decreased metabolism of ABIRATERONE caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Bosutinib.	Breast cancer [2C60-2C6Y]	[12]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[12]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[15]
Revefenacin	DMMP5SI	Moderate	Decreased clearance of ABIRATERONE due to the transporter inhibition by Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[20]
Intedanib	DMSTA36	Moderate	Decreased clearance of ABIRATERONE due to the transporter inhibition by Intedanib.	Colorectal cancer [2B91]	[21]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Pasireotide.	Cushing syndrome [5A70]	[22]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Osilodrostat.	Cushing syndrome [5A70]	[12]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of ABIRATERONE caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[23]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of ABIRATERONE caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[23]
OPC-34712	DMHG57U	Major	Decreased metabolism of ABIRATERONE caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[24]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of ABIRATERONE caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[25]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Deutetrabenazine.	Dystonic disorder [8A02]	[12]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Ingrezza.	Dystonic disorder [8A02]	[12]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of ABIRATERONE caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of ABIRATERONE caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of ABIRATERONE and Cannabidiol.	Epileptic encephalopathy [8A62]	[12]
Ripretinib	DM958QB	Moderate	Decreased metabolism of ABIRATERONE caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[10]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of ABIRATERONE caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[12]
ABT-333	DM7TOWX	Moderate	Decreased metabolism of ABIRATERONE caused by ABT-333 mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[27]
Boceprevir	DMBSHMF	Minor	Decreased metabolism of ABIRATERONE caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[8]
Brentuximab vedotin	DMWLC57	Moderate	Decreased metabolism of ABIRATERONE caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme.	Hodgkin lymphoma [2B30]	[28]
MK-1439	DM215WE	Minor	Decreased metabolism of ABIRATERONE caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Cobicistat	DM6L4H2	Minor	Decreased metabolism of ABIRATERONE caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of ABIRATERONE and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[22]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of ABIRATERONE caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[22]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of ABIRATERONE caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[30]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of ABIRATERONE caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[31]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[12]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of ABIRATERONE caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[32]
Naloxegol	DML0B41	Minor	Decreased metabolism of ABIRATERONE caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[33]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Crizotinib.	Lung cancer [2C25]	[34]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of ABIRATERONE caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[10]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Ceritinib.	Lung cancer [2C25]	[22]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of ABIRATERONE caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[35]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of ABIRATERONE caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[36]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Osimertinib.	Lung cancer [2C25]	[37]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of ABIRATERONE caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[38]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Selpercatinib.	Lung cancer [2C25]	[12]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[12]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of ABIRATERONE and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[39]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of ABIRATERONE and Idelalisib.	Mature B-cell leukaemia [2A82]	[40]
GDC-0199	DMH0QKA	Major	Decreased metabolism of ABIRATERONE caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[10]
IPI-145	DMWA24P	Moderate	Decreased metabolism of ABIRATERONE caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[41]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of ABIRATERONE caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[42]
Arry-162	DM1P6FR	Moderate	Decreased clearance of ABIRATERONE due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[10]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Vemurafenib.	Melanoma [2C30]	[22]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and LGX818.	Melanoma [2C30]	[12]
Dabrafenib	DMX6OE3	Moderate	Decreased metabolism of ABIRATERONE caused by Dabrafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[22]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of ABIRATERONE caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[43]
Rimegepant	DMHOAUG	Moderate	Decreased clearance of ABIRATERONE due to the transporter inhibition by Rimegepant.	Migraine [8A80]	[44]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Panobinostat.	Multiple myeloma [2A83]	[45]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Fingolimod.	Multiple sclerosis [8A40]	[22]
Ozanimod	DMT6AM2	Major	Decreased metabolism of ABIRATERONE caused by Ozanimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[10]
Romidepsin	DMT5GNL	Moderate	Decreased clearance of ABIRATERONE due to the transporter inhibition by Romidepsin.	Mycosis fungoides [2B01]	[46]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of ABIRATERONE caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[47]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Entrectinib.	Non-small cell lung cancer [2C25]	[12]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Rucaparib.	Ovarian cancer [2C73]	[12]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Triclabendazole.	Parasitic worm infestation [1F90]	[12]
Istradefylline	DM20VSK	Moderate	Decreased metabolism of ABIRATERONE caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[48]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of ABIRATERONE caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[49]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[50]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Lefamulin.	Pneumonia [CA40]	[51]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of ABIRATERONE caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[52]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of ABIRATERONE caused by Selexipag mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[53]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of ABIRATERONE caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[54]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Amisulpride.	Schizophrenia [6A20]	[55]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Asenapine.	Schizophrenia [6A20]	[12]
LDE225	DMM9F25	Moderate	Decreased metabolism of ABIRATERONE caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[56]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of ABIRATERONE caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[12]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of ABIRATERONE caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[10]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[22]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[12]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of ABIRATERONE caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[57]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of ABIRATERONE due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[58]
Apixaban	DM89JLN	Moderate	Decreased metabolism of ABIRATERONE caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[12]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of ABIRATERONE and Lenvatinib.	Thyroid cancer [2D10]	[12]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of ABIRATERONE and Cabozantinib.	Thyroid cancer [2D10]	[12]
Elagolix	DMB2C0E	Moderate	Decreased metabolism of ABIRATERONE caused by Elagolix mediated inhibition of CYP450 enzyme.	Uterine fibroid [2E86]	[59]
-----------


⏷ Show the Full List of 94 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Abiraterone 250 mg tablet	250 mg	Oral Tablet	Oral
Abiraterone 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
4	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
5	Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6.
6	A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
7	Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
8	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
9	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
12	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
14	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
15	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
16	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
17	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
19	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
20	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
21	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
22	Canadian Pharmacists Association.
23	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
24	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
25	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
26	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
27	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
28	Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
29	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
30	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
31	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
32	Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
33	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
34	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
36	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
37	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
38	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
39	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
40	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
41	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
42	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
44	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
45	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
47	Dimartini A "Isoniazid, tricyclics and the ''cheese reaction''." Int Clin Psychopharmacol 10 (1995): 197-8. [PMID: 8675973]
48	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
49	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
50	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
51	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
52	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
53	Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
54	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
55	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
56	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
57	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
58	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
59	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.